Latest Treatments for Tardive Dyskinesia - HealthCentral
Mar 24, 2025 · Jump To TD-Specific Meds New Antipsychotics Brain Stimulation Outlook It can be scary when you or a loved one has been diagnosed with tardive dyskinesia (TD), a disorder characterized …
Emerging Tardive Syndrome Treatments | Practical Neurology
Sep 18, 2023 · Discover cutting-edge treatments for tardive syndrome. Learn about FDA-approved meds, personalized approaches, and future perspectives in one place.
A new era in the diagnosis and treatment of tardive dyskinesia
Tardive dyskinesia (TD) is a heterogeneous, hyperkinetic movement disorder induced by dopamine-receptor blocking agents that presents a unique challenge in the treatment of psychosis. Although …
Deutetrabenazine Tablets Improve Tardive Dyskinesia Symptoms
Oct 22, 2025 · Teva Pharmaceuticals announced new data from the ongoing, real-world IMPACT-TD Registry, which demonstrates that treatment with deutetrabenazine tablets or deutetrabenazine …
New 48-Week Remission Data on Ingrezza for the Treatment of ...
Mar 20, 2025 · Check out new data from the long-term, open-label KINECT 4 study on Ingrezza capsules for the treatment of tardive dyskinesia.
New Drugs for TD: Valbenazine, Deutetrabenazine, and More
Nov 27, 2025 · Discover the new FDA-approved drugs for TD, including VMAT2 inhibitors like valbenazine (Ingrezza) and deutetrabenazine (Austedo). Learn about their efficacy and other …
Neurocrine Biosciences Presents 48-Week Remission Data on ...
Mar 20, 2025 · The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Dec 2, 2025 · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to …
What’s New in Tardive Dyskinesia, With Jonathan Meyer, MD
Jul 14, 2025 · Medications for Parkinsonism worsen tardive dyskinesia symptoms, and vice versa. Only 2 FDA-approved medications for tardive dyskinesia sit on the market—tetrabenazine and …
Ingrezza Shows 48-Week Remission – Medthority
Mar 21, 2025 · New data reveals 48-week remission in tardive dyskinesia treatment with Ingrezza valbenazine capsules.